Autologous Cell Injections for Knee Osteoarthritis Display Greater Responsiveness Than Allogenic Cellular Products and Corticosteroids in a Sex-Dependent Manner.
Mautner K., Kaiser JM., Boggess B., Hackel J., Kurtenbach C., Noonan B.
Randomized Controlled Trial with a reported sample of 480 on Knee Osteoarthritis, Osteoarthritis, published in Am J Sports Med (2025) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Randomized Controlled Trial
- Journal
- Am J Sports Med (2025)
- Country
- United States
- Reported sample size
- 480
- Source database
- PubMed
- PMID
- 41014273
- DOI
- 10.1177/03635465251365521
- NCT
- NCT03818737
Abstract (original English)
Background Age-related knee osteoarthritis (KOA) is a debilitating and progressive whole-joint disease. Despite the increased use of cell-based therapies in clinical practice to alleviate KOA symptoms, there lacks robust evidence to guide their clinical utility. We recently reported the results of our randomized controlled trial comparing corticosteroid injections (CSI) to cell-based therapies of bone marrow aspirate concentrate (BMAC), stromal vascular fraction (SVF), and allogenic umbilical cord tissue in 480 patients with Kellgren-Lawrence grade 2 to 4 KOA, finding improvements in all groups at 1 year with no statistically significant differences between groups. Here, we further examine these data from our clinical trial using a responder/nonresponder approach. Hypothesis Patients receiving a single injection of a cell-based therapy are more likely to be classified as responders than those receiving a CSI based on pain outcomes at 12 months. Study design Randomized controlled trial; Level of evidence, 2. Methods We performed an analysis of 381 patients who completed 12 months' follow-up. Responders were defined as patients with a ≥25% improvement in pain scores on the visual analog scale (VAS) or Knee Injury and Osteoarthritis Outcome Score (KOOS). Results Our hypothesis was conditionally confirmed, with BMAC having a higher response rate than a CSI. The overall responder ra
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Clinical Outcomes of Biologic Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Studies With ≥12-Month Follow-up.
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Mod Rheumatol (2026) — summary generated from the PubMed abstract.
- 2026
Mod Rheumatol - Level AMeta-analysisEurope PMC
Towards optimized rehabilitation with regenerative therapy: A systematic review and meta-analysis on the effects of cell-based injections for knee osteoarthritis
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Sports Traumatol Arthrosc (2026) — summary generated from the PubMed abstract.
- 2026
Knee Surg Sports Traumatol Arthrosc - Level ASystematic ReviewPubMed
Intra-articular fat grafting for pain relief and functioning improvement in patients with knee osteoarthritis: systematic review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Disabil Rehabil (2026) — summary generated from the PubMed abstract.
- 2026
Disabil Rehabil - Level ASystematic ReviewPubMed
Research Landscape of Stem Cell Applications in Musculoskeletal Tissue: A Scoping Review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level AMeta-analysisEurope PMC
Influence of platelet-rich plasma composition on pain and functional performance in knee osteoarthritis: a systematic review and network meta-analysis
Meta-analysis with a reported sample of 5251 on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Relat Res (2026) — summary generated from the PubMed abstract.
- 2026
- n = 5251
Knee Surg Relat Res